About the study
NIMBLE was a Phase 3 study for people with severe eosinophilic asthma who were already benefiting from mepolizumab or benralizumab. It tested whether switching to depemokimab (GSK3511294), an investigational long-acting biologic, controlled asthma attacks as well as staying on the current biologic.
Who took part
The study enrolled people who:
- Were 12 years of age or older
- Had severe eosinophilic asthma and had been benefiting from mepolizumab or benralizumab
Status at Veritas
This study has been completed. It is no longer enrolling, and it is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT04718389).